| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Institute for Animal Health, Compton, Newbury, Berkshire, United Kingdom; and
Centro Nacional de Biologia Celular y Retrovirus, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain
The attachment glycoprotein (G) of respiratory syncytial virus (RSV) is synthesized as two mature forms: a membrane-anchored form and a smaller secreted form. Mutant cDNAs were constructed that encoded one or the other form of the protein and were expressed in recombinant vaccinia viruses (rVV). Mice were immunized with rVV by dermal scarification or i.p. injection to determine the contribution of the membrane-anchored and secreted forms of the G protein on the augmentation of pulmonary pathology seen following RSV challenge. Mice scarified with rVV expressing the membrane-anchored G protein had a markedly reduced pulmonary eosinophilic response following RSV challenge compared with mice scarified with rVV expressing either wild-type or secreted G protein. The induction of pulmonary eosinophilia in rVV-primed mice was also dependent upon the route of vaccination. An eosinophilic response was not observed in any groups of mice immunized i.p. with rVV expressing any of the different forms of the G protein The difference in pulmonary pathology observed between dermal scarification or i.p. vaccinated mice was not reflected in a difference in cytokine production by splenocytes from vaccinated and challenged mice restimulated with RSV in vitro. Both groups produced significant levels of IL-4 and IL-5. These data suggest that the local APCs and lymphoid environment, together with the form of the G protein, influence pulmonary pathology following RSV challenge.
This article has been cited by other articles:
|
|
 |
|
  T. R. Johnson, M. E. Rothenberg, and B. S. Graham Pulmonary eosinophilia requires interleukin-5, eotaxin-1, and CD4+ T cells in mice immunized with respiratory syncytial virus G glycoprotein J. Leukoc. Biol., September 1, 2008; 84(3): 748 - 759. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-R. Yu, S. Kim, J.-B. Lee, and J. Chang Single Intranasal Immunization with Recombinant Adenovirus-Based Vaccine Induces Protective Immunity against Respiratory Syncytial Virus Infection J. Virol., March 1, 2008; 82(5): 2350 - 2357. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Castilow, M. R. Olson, D. K. Meyerholz, and S. M. Varga Differential Role of Gamma Interferon in Inhibiting Pulmonary Eosinophilia and Exacerbating Systemic Disease in Fusion Protein-Immunized Mice Undergoing Challenge Infection with Respiratory Syncytial Virus J. Virol., March 1, 2008; 82(5): 2196 - 2207. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Castilow, D. K. Meyerholz, and S. M. Varga IL-13 Is Required for Eosinophil Entry into the Lung during Respiratory Syncytial Virus Vaccine-Enhanced Disease J. Immunol., February 15, 2008; 180(4): 2376 - 2384. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-E. Hamelin, C. Couture, M. K. Sackett, and G. Boivin Enhanced lung disease and Th2 response following human metapneumovirus infection in mice immunized with the inactivated virus J. Gen. Virol., December 1, 2007; 88(12): 3391 - 3400. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. M. Openshaw and J. S. Tregoning Immune Responses and Disease Enhancement during Respiratory Syncytial Virus Infection Clin. Microbiol. Rev., July 1, 2005; 18(3): 541 - 555. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. R. Johnson, S. M. Varga, T. J. Braciale, and B. S. Graham V{beta}14+ T Cells Mediate the Vaccine-Enhanced Disease Induced by Immunization with Respiratory Syncytial Virus (RSV) G Glycoprotein but Not with Formalin-Inactivated RSV J. Virol., August 15, 2004; 78(16): 8753 - 8760. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. R. Johnson, M. N. Teng, P. L. Collins, and B. S. Graham Respiratory Syncytial Virus (RSV) G Glycoprotein Is Not Necessary for Vaccine-Enhanced Disease Induced by Immunization with Formalin-Inactivated RSV J. Virol., June 1, 2004; 78(11): 6024 - 6032. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Escribano-Romero, J. Rawling, B. Garcia-Barreno, and J. A. Melero The Soluble Form of Human Respiratory Syncytial Virus Attachment Protein Differs from the Membrane-Bound Form in Its Oligomeric State but Is Still Capable of Binding to Cell Surface Proteoglycans J. Virol., April 1, 2004; 78(7): 3524 - 3532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. R. Johnson, R. A. Parker, J. E. Johnson, and B. S. Graham IL-13 Is Sufficient for Respiratory Syncytial Virus G Glycoprotein-Induced Eosinophilia After Respiratory Syncytial Virus Challenge J. Immunol., February 15, 2003; 170(4): 2037 - 2045. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Prince, S. J. Curtis, K. C. Yim, and D. D. Porter Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine J. Gen. Virol., December 1, 2001; 82(12): 2881 - 2888. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. R. Johnson, J. E. Fischer, and B. S. Graham Construction and characterization of recombinant vaccinia viruses co-expressing a respiratory syncytial virus protein and a cytokine J. Gen. Virol., September 1, 2001; 82(9): 2107 - 2116. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. P. Bembridge, N. Rodriguez, R. Garcia-Beato, C. Nicolson, J. A. Melero, and G. Taylor DNA encoding the attachment (G) or fusion (F) protein of respiratory syncytial virus induces protection in the absence of pulmonary inflammation J. Gen. Virol., October 1, 2000; 81(10): 2519 - 2523. [Abstract] [Full Text]
|
|
|
|
|
|
R. García-Beato and J. A. Melero The C-terminal third of human respiratory syncytial virus attachment (G) protein is partially resistant to protease digestion and is glycosylated in a cell-type-specific manner J. Gen. Virol., April 1, 2000; 81(4): 919 - 927. [Abstract] [Full Text]
|
|
|
|
|
|
R. A. Tripp, D. Moore, J. Winter, and L. J. Anderson Respiratory Syncytial Virus Infection and G and/or SH Protein Expression Contribute to Substance P, Which Mediates Inflammation and Enhanced Pulmonary Disease in BALB/c Mice J. Virol., February 15, 2000; 74(4): 1614 - 1622. [Abstract] [Full Text]
|
|
|
|
|
|
G. P. Bembridge, J. A. Lopez, R. Bustos, J. A. Melero, R. Cook, H. Mason, and G. Taylor Priming with a Secreted Form of the Fusion Protein of Respiratory Syncytial Virus (RSV) Promotes Interleukin-4 (IL-4) and IL-5 Production but Not Pulmonary Eosinophilia following RSV Challenge J. Virol., December 1, 1999; 73(12): 10086 - 10094. [Abstract] [Full Text]
|
|
|
|
|
|
T. R. Johnson and B. S. Graham Secreted Respiratory Syncytial Virus G Glycoprotein Induces Interleukin-5 (IL-5), IL-13, and Eosinophilia by an IL-4-Independent Mechanism J. Virol., October 1, 1999; 73(10): 8485 - 8495. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Tripp, D. Moore, L. Jones, W. Sullender, J. Winter, and L. J. Anderson Respiratory Syncytial Virus G and/or SH Protein Alters Th1 Cytokines, Natural Killer Cells, and Neutrophils Responding to Pulmonary Infection in BALB/c Mice J. Virol., September 1, 1999; 73(9): 7099 - 7107. [Abstract] [Full Text]
|
|
|
|
|
|
A. Srikiatkhachorn, W. Chang, and T. J. Braciale Induction of Th-1 and Th-2 Responses by Respiratory Syncytial Virus Attachment Glycoprotein Is Epitope and Major Histocompatibility Complex Independent J. Virol., August 1, 1999; 73(8): 6590 - 6597. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
